a16z co-founders Marc Andreessen and Ben Horowitz discuss the shift to a decentralized media ecosystem, their investment thesis on supply-driven markets, and the transformative impact of AI. They detail the a16z model of leveraging reputation as a core asset to turn inventors into CEOs and explain why AI represents a fundamental reinvention of computing that will unlock unprecedented growth.
Ben Horowitz of Andreessen Horowitz discusses how AI is reshaping venture capital, detailing the firm's strategy for managing partners, verticalizing teams, and evaluating investments in real-time. He breaks down the current AI cycle, arguing that application design and model orchestration are key, and explains why the current market's growth is driven by real demand, not just hype.
a16z's David Haber and Plaid CEO Zach Perret chart the dramatic seasons of fintech, from the explosive VC-fueled boom of 2020-2021 to the deep freeze of 2022 and its current resurgence. They explore the transformative forces reshaping the industry today, including AI's dual role as both a primary tool for sophisticated fraud and the ultimate defense against it. The conversation also covers the rise of embedded finance, the renewed importance of deposits, and how incumbents are finally embracing external software, with Plaid's own journey serving as a microcosm of the industry's evolution.
Silicon Valley's historical alliance with US defense fractured over 15 years of hostility, but is now being rebuilt under the "American Dynamism" thesis, driven by the geopolitical realities of Ukraine and competition with China. This shift prioritizes building in the physical world—defense, energy, manufacturing—by leveraging software, AI, and autonomy to innovate faster than legacy, five-year-plan-based incumbents and win by doubling down on America's chaotic creativity.
Venture capitalists Elliot Hershberg and Lada Nuzhna analyze the structural crises facing the biotech industry, from Eroom's Law driving drug development costs to $2.5 billion, to China's rapid, low-cost clinical trials outmaneuvering US startups. They argue that for American biotech to survive, it must shift from competing on commoditized platforms to inventing entirely new modalities and medicines that are impossible to create without bleeding-edge tools like AI, targeting massive opportunities like aging.
The panel discusses the shifting AI hardware landscape as Oracle and OpenAI bet on AMD, challenging Nvidia's dominance. They also analyze a US government report on the risks of the DeepSeek model, debate the viability of Reflection AI's new $2B open-source venture, and dissect the story of a VC fund replacing analysts with AI agents.